This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bettany, G.E.A. Articles by Powell-Tuck, J. Search for Related Content PubMed PubMed Citation Articles by Bettany, G.E.A. Articles by Powell-Tuck, J. Social Bookmarking                         What's this?

Metabolic Effects of Adjuvant Recombinant Human Growth Hormone in Patients With Continuing Sepsis Receiving Parenteral Nutrition

Department of Human Nutrition, The Royal London Hospital, Whitechapel, London

C. Camacho-Hubner, MD

Department of Endocrinology, St Bartholomew's Hospital, London

O. Obeid, PHD

Department of Human Nutrition, The Royal London Hospital, Whitechapel, London

D. Halliday, PHD

Clinical Research Centre, St Mary's Hospital, Paddington, London

J. Powell-Tuck, MD

Department of Human Nutrition, The Royal London Hospital, Whitechapel, London

Background: Adjuvant growth hormone is advocated for treating the catabolism of prolonged sepsis not corrected by parenteral nutrition alone. Methods: An open study was performed in which eight patients whose postabsorptive resting energy expenditure was persistently elevated by a mean of 19% as a result of continuing sepsis were randomized to receive 0.03 or 0.06 mg/kg recombinant human growth hormone (rhGH) each evening for 7 days adjuvant to total parenteral nutrition. Plasma concentrations of growth hormone, insulin, insulin-like growth factors 1 and 2 (IGF-1 and -2) and their binding proteins IGFBP-1 and -3 were measured before and after rhGH, and their relationship with rates of whole-body protein turnover was determined in the morning in the postabsorptive state by using L-[1-¹³C]leucine. Results and Conclusions: Before rhGH, the patients were hyperinsulinemic (mean, 44.4 mU/L) but had growth hormone levels within the normal range (< 10 mU/L). After the seventh dose of rhGH, nocturnal growth hormone concentrations rose to a mean of 35.3 ± 26.1 and 61.3 ± 21.05 mU/L for the low and higher dose groups, respectively. Morning IGF-1 concentrations showed a small increase during treatment, rising from a mean of 241.3 ± 99.0 to 301.7 ± 167.3 ng/mL for the low-dose group and from 214.5 ± 74.6 to 294.1 ± 116.9 ng/mL for the higher-dose group. IGF-2 increased slightly by 89 ± 39 and 75 ± 49 ng/mL for the low and higher doses, respectively. IGFBP-1 and -3 and insulin did not change. The balance between nitrogen input and urinary urea nitrogen increased after rhGH by a mean of 5.3 g/d with no differences between the two dosage groups (4.74 ± 1.56 g/d for the higher dose, 5.94 ± 3.70 g/d for the lower). No significant changes were observed in whole-body protein turnover after a 1-week course of rhGH. (Journal of Parenteral and Enteral Nutrition 22:199-205, 1998)

Journal of Parenteral and Enteral Nutrition, Vol. 22, No. 4, 199-205 (1998)
DOI: 10.1177/0148607198022004199


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?